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ABSTRACT
CCN2 is a matricellular protein involved in several crucial biological
processes. In particular, CCN2 is involved in cartilage development
and in osteoarthritis. Ccn2 null mice exhibit a range of skeletal
dysmorphisms, highlighting its importance in regulating matrix
formation during development; however, its role in adult cartilage
remains unclear. The aim of this study was to determine the role of
CCN2 in postnatal chondrocytes in models of post-traumatic
osteoarthritis (PTOA). Ccn2 deletion was induced in articular
chondrocytes of male transgenic mice at 8 weeks of age. PTOA was
induced in knees either surgically or non-invasively by repetitive
mechanical loading at 10 weeks of age. Knee joints were harvested,
scannedwithmicro-computed tomography and processed for histology.
Sections were stained with Toluidine Blue and scored using the
Osteoarthritis Research Society International (OARSI) grading system.
In the non-invasive model, cartilage lesions were present in the lateral
femur, but no significant differences were observed between wild-type
(WT) and Ccn2 knockout (KO) mice 6 weeks post-loading. In the
surgical model, severe cartilage degeneration was observed in the
medial compartments, but no significant differences were observed
between WT and Ccn2 KO mice at 2, 4 and 8 weeks post-surgery. We
conclude that Ccn2 deletion in chondrocytes does not modify the
development of PTOA in mice, suggesting that chondrocyte expression
of CCN2 in adults is not a crucial factor in protecting cartilage from the
degeneration associated with PTOA.
This article has an associated First Person interview with the first author
of the paper.
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INTRODUCTION
Osteoarthritis (OA) is a major chronic degenerative disease of the
joint, with limited therapies available to inhibit or slow disease
progression. Mechanical trauma represents a major risk factor for
OA, with mouse models of post-traumatic OA (PTOA) being widely
used to study OA development. These include surgical models for
development of different degrees of OA severity (Kamekura et al.,
2005) and non-invasive repetitive joint trauma models, including
the one established by Poulet et al. (2011). Both surgical and
non-invasive models show similar hallmarks to those seen in human
OA, including progressive articular cartilage (AC) degradation,
subchondral bone sclerosis, osteophyte formation and synovial
fibrosis and activation. In this study, we used both a surgical model
and a non-invasive model to determine the role of the matricellular
protein CCN2 in severe and moderate PTOA.
CCN2, formerly known as connective tissue growth factor (CTGF)
(Perbal, 2018b), is a matricellular protein involved in key cellular
functions including proliferation, adhesion anddifferentiation (Kubota
andTakigawa, 2015), alongwith several complex biological processes
including chondrogenesis (Perbal, 2004). Deletion of Ccn2 during
development demonstrated its essential role as a regulator of skeletal
development by promoting endochondral ossification through the
proliferation and differentiation of growth plate chondrocytes (Ivkovic
et al., 2003), consistent with the ability of CCN2 to promote
differentiation and proliferation of cultured chondrocytes.
CCN2 is expressed in adult AC, albeit at low levels (Tang et al.,
2018; Nishida et al., 2004), and its expression increases
significantly in OA chondrocytes (Omoto et al., 2004; Shimo
et al., 2000; Takigawa et al., 2003). In addition, CCN2 promotes the
expression of matrix genes and has been suggested as a potential
cartilage repair factor (Nishida et al., 2004). Likewise, continuous
cartilage-specific overexpression of CCN2 protects joints from age-
related development of OA, highlighting a chondroprotective role of
CCN2 (Itoh et al., 2013). Conversely, CCN2 overexpression in the
synovial lining of mouse knee joints causes transient fibrosis and
cartilage damage (Blaney Davidson et al., 2006). Moreover, mice in
which CCN2 was globally deleted postnatally were protected from
surgically induced OA; this effect was linked to the ability of CCN2
to activate latent TGFβ (also known as TGFB1-3) (Tang et al.,
2018). These divergent results are consistent with the fact that
CCN2, as a matricellular protein, has cell type- and context-
dependent effects (Perbal, 2018a); it can promote the expression of
extracellular matrix genes in chondrocytes or promote fibrosis/OA
depending on the context. The elucidation of the precise role of
CCN2 in joint health and OA, chondroprotective versus profibrotic/
pro-osteoarthritic, needs to be explored further genetically.
Therefore, to gain a better understanding of the role of CCN2 in
adult cartilage, we exposed chondrocyte-specific Ccn2 knockout
mice to two distinct models of PTOA.
RESULTS
Ccn2wassuccessfully deleted in chondrocytes inadultmice
To verify that deletion of Ccn2 in chondrocytes had occurred in
response to tamoxifen injection, a tail tip containing ACAN-
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expressing cells from the intervertebral disc and endplates was taken
post-cull from each individual mouse, and PCR was performed on
extracted genomic DNA for genetic recombination and exon
deletion. All mice contained a 1000 bp band corresponding to the
floxed Ccn2 allele, and Cre+/o mice contained an additional band at
∼500 bp corresponding to the allele generated by Cre
recombination resulting in the Cre-mediated deletion of Ccn2
(Fig. 1). CreWT mice showed no recombination. To validate the
efficiency of the CreERT2 system and the subsequent deletion of the
transgene in these new Acan −30 kb CreERT2 mice, Ccn2fl/fl with
Cre+/o (Ccn2 KO) mice were crossed with a tdTomato reporter
mouse, which enabled detection of recombined CreERT2 via
fluorescence, after administration of tamoxifen to the mice. In
control corn oil-treated mice, no tdTomato was seen in the whole
joint cells (only a chondrocyte was positive; Fig. 1), demonstrating
that no recombination of CreERT2 occurred. After tamoxifen
treatment, there was clear recombination of CreERT2 as evident by
the intense expression of tdTomato protein in all chondrocytes
located in both the AC and the growth plate (Fig. 1).
Conditional Ccn2 deletion in chondrocytes does not prevent
the development of OA in a non-invasive loading model of
trauma-induced OA
Mice [Ccn2 KO and wild type (WT)] were treated with tamoxifen
then mechanically loaded to induce PTOA. Histological
examination of the loaded limb in both WT (n=13) and Ccn2 KO
(n=14) mice showed the development of OA lesions, with loss of
hyaline AC and exposure of the articular calcified cartilage
primarily in the lateral femur (Fig. 2). Assessment of the severity
of the lesions in each compartment throughout the entire
tibiofemoral joint (medial and lateral, tibia and femur) showed no
significant differences in the AC lesion mean, maximum and
summed severity scores between WT and Ccn2 KO mice. Micro-
computed tomography (micro-CT) analysis of the epiphyseal bone
of the lateral femur and tibia showed no differences in bone volume/
tissue volume (BV/TV) between WT and KO (Fig. 2). Together,
these data indicate that deletion of Ccn2 postnatally from ACAN-
expressing chondrocytes had no effect on the development of OA in
a non-invasive model of moderate PTOA.
Ccn2 deletion specifically in chondrocytes does not prevent
the development of OA in a surgical model of severe PTOA
To confirm that deletion of Ccn2 in chondrocytes of adult mice had
no effect on OA, a second model of PTOA was used. This model
incorporated a different Cre (Acan −10 kb CreERT2), which had
been shown previously to be expressed in articular chondrocytes
(Han and Lefebvre, 2008). At 2 weeks post-surgery, moderate AC
lesions were already visible in the medial compartment of both WT
and Ccn2 KO mice, with exposure of the underlying calcified
cartilage (Fig. 3). At 4 weeks post-surgery, the damage was
extensive, with both WT and Ccn2 KO mice suffering substantial
loss of AC in the medial compartment of the tibiofemoral joint. By
8 weeks post-surgery there was widespread, significant damage
across the entire medial side of the tibiofemoral joint in bothWTand
Ccn2 KO mice, including near-complete loss of AC. Cartilage
lesion scoring showed no significant differences between WT and
Ccn2 KO at all time points.
DISCUSSION
The aim of this study was to determine the postnatal role of CCN2 in
AC during PTOA in two different models. We have found that
despite its importance during skeletal development and its increased
expression by OA chondrocytes, CCN2 in AC chondrocytes in adult
joints did not play a significant role in preventing PTOA
development.
A number of studies have focused on the regenerative ability of
CCN2 owing to its role in cellular proliferation and differentiation
during chondrogenesis (Takigawa et al., 2003; Shimo et al., 2000).
Indeed, it has been shown in vitro that CCN2 induces chondrocyte
proliferation and differentiation, with increased synthesis of
cartilage matrix proteins, including proteoglycans, ACAN and
collagen types II and X (Shimo et al., 2000; Fujisawa et al., 2008).
Subsequently, it was found that CCN2 plays a role in
chondrogenesis during fractured bone healing; CCN2 expression
in this process responds to MAPK and retinoid receptor gamma
signalling pathways (Shimo et al., 2019, 2005, 2020; Nakata et al.,
2002; Yosimichi et al., 2006). CCN2 expression is highly regulated
by TGFβ (Song et al., 2007), with its promoter transcriptional
activity maintained by a TGFβ response element (Eguchi et al.,
Fig. 1. Confirmation of Cre recombination and Ccn2fl/fl transgene deletion in chondrocytes in−30 kb Acan CreERT2 adult mice. (A) Genotyping from tail
tips, the genomic DNA fromWTandCcn2Cre+/o mice showed the presence of the CCN2 flox product in all mice (first band) and the additional lower band in Cre+/o
mice only, (+/o) ∼500 bp in size, confirming Cre recombination and deletion of the CCN2 floxed product. (B-D) Histological images of the tibial epiphysis
in Ccn2 Cre+/o crossed with the tdTomato reporter mouse 4 weeks after the last corn oil control injection (B) or tamoxifen injection (C,D). Corn oil treatment
resulted in no recombination (except one single chondrocyte stained red, arrow inB; blue staining of nuclei withHoechst stain). (C,D) Tamoxifen treatment resulted in
expression of tdTomato fluorescence (red) in chondrocytes throughout the AC and growth plate (top and bottom arrows, respectively). Scale bars: 100 µm.
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2001). The importance of CCN2 in chondrogenesis can be seen in
the severe developmental phenotype in mice lacking CCN2; indeed,
Ivkovic et al. (2003) showed impaired chondrocyte proliferation and
matrix deposition in the hypertrophic zones of growth plate cartilage
linked to defective matrix remodelling and growth plate
angiogenesis, concurrent with decreased vascular endothelial
growth factor (VEGF). In parallel, overexpression of CCN2 in
chondrocytes led to enhanced endochondral ossification, with
elongated bones, increased proteoglycans and collagen II content
in newborn transgenic mice, mediated in part by enhanced
accumulation of insulin-like growth factors (IGFs) (Tomita et al.,
2013). In adults, CCN2 overexpression was shown to be
chondroprotective, by inhibiting ageing-induced development of
OA, with increased adult AC matrix synthesis and decreased matrix
degrading enzymes (Itoh et al., 2013). Its role in chondrogenesis
highlighted its potential as a possible regenerative therapy for the
treatment of OA, particularly given that exogenously added
recombinant CCN2 did not stimulate hypertrophy of chondrocytes
in vitro (Nishida et al., 2002). Moreover, treatment of AC defects
with recombinant CCN2 showed repaired cartilage to be structurally
similar to healthy AC (Nishida et al., 2004).
A study by Tang et al. (2018) showed that a postnatally induced
global deletion ofCcn2 caused a thickening of cartilage that resulted
in protection from ageing-induced OA. Deletion of Ccn2 from all
cells was induced in adult mice, and post-traumatic surgical OA
induction resulted a decrease in AC degradation, increased cartilage
thickness and activation of canonical TGFβ signalling SMAD2
phosphorylation. Their study also showed that CCN2 was involved
in the regulation of TGFβ activation by sequestration of its latent
form in the matrix and activation of the cell surface receptor
TGFβR3. The authors suggested that in global Ccn2 deletion,
chondrocytes might be responding to increased soluble latent TGFβ
from lack of sequestration in the cartilage matrix or produced by
other non-AC tissues. To test whether this phenotype is induced
primarily by cartilage or by other joint tissues, we selectively
deleted Ccn2 in chondrocytes in adult mice and assessed post-
traumatic OA development. The lack of effect of chondrocyte-
specific compared with global deletion of Ccn2 in mice (which
protected from development of OA) suggests that CCN2 expression
in other tissues, including those surrounding the tibiofemoral joint,
such as synovium and epiphyseal bone, might be required for
protection from OA. In addition, it has been shown that CCN2 can
be found in serum and synovial fluid (Honsawek et al., 2012; Yang
et al., 2017), which might compensate the absence of CCN2 in
chondrocytes in the present study.
CCN2 is expressed by a number of other cells/tissues in the joint,
such as synovial fibroblasts (Blaney Davidson et al., 2006), and has
been shown to induce hallmarks of OA such as synovial fibrosis,
cartilage degeneration and osteophyte formation. It is also entirely
feasible that the lack of effect seen in chondrocyte-specific deletion
Fig. 2. Deletion of Ccn2 in chondrocytes does not
prevent OA development in a non-invasive
loading model of PTOA. (A-D) Toluidine Blue-
stained sections of the tibiofemoral joint of WT (A,B)
and Ccn2fl/fl KO (C,D) mice showing development of
AC lesions localized to the lateral femur in loaded
knee joints (arrows) 6 weeks after the last loading
episode. (E-G) AC lesion severity scores across the
whole knee joint showing no differences between WT
andCcn2fl/flKOmice in summedmaximum scores (E)
or in maximum (F) and mean (G) lesion severity
scores for each joint compartment. (H,I) BV/TV of the
epiphyseal bone in the lateral (Lat) femur (H) and
lateral tibia (I) showed no significant difference in bone
structure between WT and Ccn2fl/fl KO. Whiskers
representminimum andmaximum values, with box for
interquartile range with median, and showing
individual animals. LF, lateral femur; LT, lateral tibia;
MF, medial femur; MT, medial tibia. Scale bars:
200 µm in A,C; 100 µm in B,D. Grey boxes, WT; white
boxes, Ccn2fl/fl KO. Number of animals: n=13 WT and
n=14 Ccn2 KO. Statistical test performed: Mann–
Whitney U-test and Wilcoxon signed-rank tests for
lesion severity, and unpaired Student’s t-test for bone
measurements.
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in our studies is linked to secretion of CCN2 from these other joint
tissues and its release into the joint space, thereby preventing any
effects of chondrocyte-specific deletion on OA development from
being observed. It has been shown that fibrosis is highly linked to
TGFβ-induced CCN2 expression and that these tissues can also
express high levels of matrix degrading enzymes (such as MMPs)
(Blaney Davidson et al., 2006). This would therefore suggest that
pathological non-AC joint tissues, such as synovial fibrosis, are
controlled by CCN2 expression during post-traumatic OA
development and contribute to AC degradation.
The effects of Ccn2 deletion on chondrogenesis and OA
development are similar to those of other CCN members. Indeed,
deletion of Ccn4, also known as Wisp1, was shown to promote
chondrogenesis and cartilage repair (Yoshioka et al., 2016),
whereas it can also promote OA development (van den Bosch
et al., 2017). The latter was linked to differential effects of Ccn4
deletion on OA tissues, with synovial tissue being more responsive
to Ccn4 deletion than cartilage in OA joints. These data therefore
suggest a protective effect of CCN4 in cartilage, but a pro-
arthritogenic role via synovial fibrosis. Similar mechanisms could
also be involved in Ccn2 deletion, whereby its protective role
focuses on chondrogenesis (during development and facture repair)
and its pathological role targets mainly fibrotic events (synovial
fibrosis), therefore explaining our lack of effects of Ccn2 deletion in
chondrocytes.
Other cells, including those derived from mesenchymal stem
cells (MSCs) and MSC-like progenitor cells, might also have
affected the levels of CCN2 in the joint. These cells are present in all
joint tissues and can differentiate into several populations of cells,
including those with chondrogenic potential (Barry and Murphy,
2013). These cells, which are not targeted for Ccn2 deletion, might
have been recruited in response to lesion formation, leading to
increased expression of CCN2 in the joint and subsequent loss of the
KO effect on OA development.
It should be noted that the absence of any observable responses in
our studies is not a result of insufficient Cre recombinase activity
and the subsequent deletion of Ccn2 from chondrocytes. The
efficiency of Cre recombinase activity for the Acan −10 kb
enhancer had been tested previously and shown to be effective
(Cascio et al., 2014), and the new −30 kb enhancer showed a
proportionally greater number of chondrocytes expressing the
transgene (Li et al., 2018). To confirm the efficiency of this new
Fig. 3. Deletion of Ccn2 in chondrocytes does not mitigate AC lesion severity in a surgical model of severe PTOA. (A-C) Toluidine Blue-stained sections
from WT and Ccn2fl/fl KO mice 2, 4 and 8 weeks post-surgery showing development of OA on the medial tibia (arrows) in both WT (top) and Ccn2fl/fl KO
(bottom). (D-L) Maximum and mean lesion severity in each individual joint compartment and summedmaximum scores showing no significant difference between
OA severity in WT and Ccn2fl/fl KO mice at 2 weeks (D-F), 4 weeks (G-I) and 8 weeks (J-L) post-surgery. Whiskers represent minimum and maximum values, with
box for interquartile range with median, and showing individual animals. LF, lateral femur; LT, lateral tibia; MF, medial femur; MT, medial tibia. Scale bars:
200 µm in left column (A-C); 100 µm in right column (A-C). Grey boxes,WT; white boxes,Ccn2fl/fl KO. Number of animals: 2 weeks, n=4WTand n=14 KO; 4 weeks,
n=7 WT and n=7 KO; 8 weeks, n=7 WT and n=8 KO. Statistical test: Mann–Whitney U-test test and Wilcoxon signed-rank test.
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Acan-specific CreERT2 system, Acan−30 kb CreERT2 withCcn2fl/fl
mice were crossed with tdTomato reporter mice (Fig. 2), which
allowed for detection of Cre recombinase activity following
tamoxifen injection by visualisation of the tomato fluorescence
compared with oil-injected control mice, and confirmed
recombination, hence CCN2 deletion, from all AC chondrocytes.
Furthermore, the use of two different Acan Cre systems to drive Cre
recombinase expression in chondrocytes ensured that any responses
were independent of Cre activity targeting and were most likely to
be a direct result of the action of Ccn2 deletion.
In the present study, we used two models of PTOA, with different
severities of OA progression. The non-invasive loading of the knee
has previously been shown to induce moderate OA lesions on the
lateral femur (Poulet et al., 2011), whereas surgical intervention is
known to lead to a higher degree of OA severity. The importance of
using different models pertains to the fact that, although similar
pathologies can be seen in both models, both can trigger different
cellular responses linked to the severity of the disease. For example,
the surgical model might trigger more severe inflammatory
responses. In addition, the mechanical environment is severely
affected in the surgical model throughout the whole study, whereas
the traumatic loads are applied at specific and controlled times, with a
maximum of six episodes of 7 min; the rest of the time, the
mechanical environment is relatively normal compared with that
engendered by surgical instability. In future studies, the lack of effects
of chondrocyte-specific CCN2 expression in adults could be tested in
other models of OA, including ageing- and obesity-induced OA.
In conclusion, this study showed, through the use of two models
of PTOA, that CCN2 expression by chondrocytes is not required for
maintenance of cartilage in adults. Further work will confirm
whether CCN2 expression by other non-cartilage tissues within the
joint might be involved in development of PTOA.
MATERIALS AND METHODS
Animals
All work was carried out in accordancewith the UKHomeOffice guidelines
and regulations under the Animals (Scientific Procedures) Act 1986. All
mice (C57CBA background) were housed in the specific pathogen-free
biological services unit at the University of Liverpool, UK and housed in
cages of up to five mice, with 12 h-12 h light-dark cycle and ad libitum food
and drink. Using chondrocyte-specific Acan enhancers, two conditional
Ccn2 KO mouse models were generated. The first contained an Acan
−10 kb CreERT2 enhancer, as described by Han and Lefebvre (2008). This
produced Acan −10 kb CreERT2×Ccn2fl/fl mice, in which Ccn2 was deleted
from articular chondrocytes. The second contained an Acan −30 kb
CreERT2 enhancer described by Li et al. (2018). This produced Acan
−30 kb CreERT2×Ccn2fl/fl mice, in which Ccn2 was deleted from all
chondrocytes. Deletion of Ccn2 was regulated using a tamoxifen-inducible
CreERT2 in adult mice, to avoid effects of Ccn2 deletion during
development and growth. For visualisation of the Cre recombinase
efficiency in mouse knee joints, Rosa26-loxP-STOP-loxP-tdTomato
(R26R-tdTomato; JAX7914) were mated with Acan −30 kb CreERT2 mice.
Tamoxifen induction of Acan CreERT2
Before the start of all in vivo experiments, deletion of Ccn2 or STOP in
reporter tdTomato using AcanCreERT2 was induced at 8 weeks of age using
tamoxifen (Sigma-Aldrich, UK). All mice, whether WT or Ccn2fl/fl, were
administered tamoxifen intraperitoneally at a dose of 1 mg/10 g body
weight on days 1, 3 and 5 and were weighed before injection on each day.
After tamoxifen injections, mice were left for 1 week before any
Fig. 4. Description of the method for the micro-CT
analysis of the knee joint epiphyseal bone.
(A) Tibial reorientation in DataViewer (Bruker
microCT; showing the three planes of view: top,
coronal; bottom left, transaxial; bottom right, sagittal),
with the growth plate and posterior edge of the tibia
aligned in the different views along the blue line.
(B,C) Manual drawing of the region of interest (red)
in the tibial epiphysis (B) and selection of the lateral
compartment (C) in CTAn (Bruker microCT).
(D) Femur orientation in DataViewer, with the shaft
of the femur aligned with the dotted yellow lines. The
region of interest will then be confined to the posterior
aspect of the joint (below the yellow dotted line).
(E) Drawing of the region of interest in CTAn to include
the whole lateral condyle of the femur.
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experimental work commenced. The tdTomato mice were sacrificed
4 weeks after last tamoxifen injection.
Non-invasive mechanical loading model of PTOA
Right knees of 10-week-old male Acan −30 kb CreERT2×Ccn2fl/fl [n=13
(CreWT), n=14 (Cre+/o)] mice were loaded non-invasively, using a model
previously described (Poulet et al., 2011) to induce PTOA. Briefly, the
mouse was anaesthetised, and the right hindlimb was placed in a custom-
made cup, with the knee in flexion. A peak load of 9 N was applied for
0.05 s, with a rise and fall time of 0.025 s and a baseline hold time of 9.9 s
for 40 cycles. A baseline load of 2 N was applied to keep the tibia in place
during peak loading. All mice were subjected to this pattern three times per
week for 2 weeks. Loading was performed using an ElectroForce 3100 (TA
Instruments, USA). Mice were weighed after each loading episode, and on a
weekly basis after completion of the loading regimen. All mice were
sacrificed 6 weeks post-loading and samples prepared for micro-CT and
histological analysis.
Surgical model of PTOA
Left knee joints of 10-week-old Acan −10 kb CreERT2×Ccn2fl/fl mice
underwent surgical transection of the medial meniscus (MM) and the medial
meniscotibial ligament (MMTL). Mice were induced and maintained under a
plane of general anaesthesia using isoflurane during the surgical procedure. A
small incision was made over the medial aspect of the patella tendon and the
joint capsule incised. Using blunt dissection, small amounts of fat were
removed to permit visualisation of the MM and MMTL. Using a scalpel, the
MM and MMTL were transected using an upwards motion from the cranial
horn of the MM on the proximal tibial plateau. Once transected, the joint
capsule and the skin were sutured. Mice were immediately transferred to a
heated postoperative recovery room. They were monitored daily to ensure
that they were in good health. Mice were sacrificed 2 weeks postoperatively
[n=4 (CreWT), n=14 (Cre+/o)], 4 weeks postoperatively [n=7 (CreWT), n=7
(Cre+/o)] and 8 weeks postoperatively [n=7 (CreWT), n=8 (Cre+/o)].
Samples were prepared for micro-CT and histological analysis.
Specimen preparation
All animals were sacrificed by cervical dislocation. Experimental and
contralateral joints were dissected, immediately fixed in 10% neutral
buffered formalin for 24 h and transferred to 70% ethanol for storage.
Micro-CT analysis
Experimental and contralateral joints from the non-invasive mechanical
loading model were scanned at a resolution of 4.5 µm using a 0.25 mm
aluminium filter, with a rotation step of 0.6° (Skyscan 1272; Bruker
microCT, Belgium). Image reconstruction was performed using NRecon
software (Bruker microCT, Belgium), followed by manual selection of
regions of interest for the tibial and femoral epiphyses. Datasets were first
oriented in DataViewer (Bruker microCT) to ensure that all samples were
analysed in the same orientation depending on the structure analysed
(Fig. 4A,E). Newly orientated samples were opened in CTAn (Bruker
microCT) and regions of interest drawn to include the lateral condyles; these
included the epiphysis delimited by the joint space and the growth plate, and
the edges of the articulating surface for each condyle. The BV/TV ratio was
determined in CTAn. Datawere tested for normality, and unpaired Student’s
t-test was used for statistical evaluation, with significance set at P<0.05,
comparing osteoarthritic WT and Ccn2fl/fl KO joints.
Histological analysis
Samples were decalcified in either 10% EDTA (Sigma-Aldrich, UK) for
2 weeks or 10% formic acid (Sigma-Aldrich, UK) for 1 week. Once
decalcified, samples were given a processing number independent of their
genotype, processed, paraffin embedded in either the coronal (surgical model)
or sagittal plane (loading model), and 6-µm-thick sections were taken
throughout the entire joint. Sections across the joint at 120 µm intervals were
stained with ToluidineBlue/Fast Green (0.04% in 0.1 M sodium acetate buffer,
pH 4.0), and cartilage lesion severity was graded using the Osteoarthritis
Research Society International (OARSI) histopathology initiative scoring
method (Glasson et al., 2010). Grading each of the four compartments of the
tibiofemoral joint (lateral and medial tibia and femur) throughout the entire
joint allowed for the determination of a maximum lesion grade (most severe
lesion) for the whole joint and each individual compartment. The mean score,
which involved determining the average grade across multiple slides, was
calculated for each joint and each compartment (Poulet et al., 2011). The
summed score was determined by adding together the maximum score of each
compartment per joint. Osteophyte formation was graded histologically using
the scale described by Kamekura et al. (2005). Statistical analysis was
performed using theMann–WhitneyU-test and theWilcoxon signed-rank test.
Data are presented as box plots of interquartile range, median, minimum and
maximum, showing all individuals.
Cryosectioning
Samples from tdTomato were dissected, fixed in 4% paraformaldehyde at
4°C for 24 h, decalcified in 10% EDTA for 2 weeks, embedded using OCT
embedding media (Tissue-Tek, Sakura Europe) in either the coronal (WT)
or sagittal (Cre+/o) plane, and stored at −80°C until required. Sections were
taken at 5 µm thickness until the middle of the joint was reached. A section
showing the entire tibiofemoral joint was then collected and stained with
Hoechst stain for 30 min. Images were obtained using a Zeiss Axio
Observer apotome microscope (Zeiss, Germany).
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